Stock Events

Allogene Therapeutics 

$2.52
65
-$0.02-0.79% Friday 20:00

Statistics

Day High
2.59
Day Low
2.47
52W High
6.05
52W Low
2.23
Volume
1,747,944
Avg. Volume
2,581,836
Mkt Cap
430.55M
P/E Ratio
-1.4
Dividend Yield
-
Dividend
-

Earnings

13MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.7
-0.59
-0.48
-0.37
Expected EPS
-0.41
Actual EPS
-0.38

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALLO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

9.8$Average Price Target
The highest estimate is $17.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Health Technology
Biotechnology
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Show more...
CEO
Employees
232
Country
US
ISIN
US0197701065

Listings